Dr. Mehta-Shah on the Variations of the CHOP Regimen in PTCL


Neha Mehta-Shah, MD, MSCI, discusses variations of CHOP-based chemotherapy in peripheral T-cell lymphoma.

Neha Mehta-Shah, MD, MSCI, associate professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, and medical oncologist, Siteman Cancer Center, discusses variations of CHOP-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) in peripheral T-cell lymphoma (PTCL).

Although the CHOP regimen has remained a standard treatment in many lymphomas, deviations from or additions to this standard are important to consider for some patients, Mehta-Shah says. One common CHOP-based regimen is CHOEP, which adds etoposide chemotherapy for 3 days with each cycle of CHOP, Mehta-Shah notes.

Another option is brentuximab vedotin (Adcetris) plus CHP, known as BV-CHP, which has demonstrated improved progression-free survival and overall survival (OS) in patients with anaplastic large cell lymphoma, a disease which expresses the protein CD30, the target of brentuximab vedotin, Mehta-Shah explains. However, BV-CHP is still an effective approach in patients with other forms of lymphoma, such as PTCL not otherwise specified (NOS) or angioimmunoblastic T-cell lymphoma, Mehta-Shah says.

For instance, the phase 3 ECHELON-2 study (NCT01777152), which compared BV-CHP with CHOP alone, included patients who did not have anaplastic large cell lymphoma. This study demonstrated an OS benefit with BV-CHP in these patients, with a 5-year OS rate of 46.2% in patients with PTCL NOS vs 35.9% with CHOP alone, Mehta-Shah concludes.

Related Videos
Arpita Desai, MD
Qian (Janie) Qin, MD
Melissa L. Johnson, MD
Adrienne Phillips, MD, MPH
Jeffrey S. Weber, MD, PhD
Joseph P. McGuirk, DO, an expert on lymphoma
Joseph P. McGuirk, DO, an expert on lymphoma
Manojkumar Bupathi, MD, MS
Mylin A. Torres, MD
Bernd Kasper, MD, PhD